Scientists in Singapore have developed a diagnostic test, used in over 90 countries, to detect neutralizing antibodies for multiple viruses like COVID-19, Ebola, and Nipah. This test, called sVNT, identifies antibodies capable of neutralizing these pathogens, providing a functional measure of immunity. It helps assess vaccine effectiveness, inform future vaccine formulations, support contact tracing, and even trace animal transmission. Safer than using live pathogens, the sVNT uses only viral spike proteins. Building on the 2020 cPass test, it addresses limitations in detecting newer COVID-19 variants and is now used by institutions like Oxford and Melbourne Universities for research and surveillance.
This article has been processed for multi-language support.